Share This Page
Drug Price Trends for NDC 65862-0082
✉ Email this page to a colleague
Average Pharmacy Cost for 65862-0082
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GLYBURIDE-METFORMIN 5-500 MG | 65862-0082-01 | 0.19780 | EACH | 2025-11-19 |
| GLYBURIDE-METFORMIN 5-500 MG | 65862-0082-05 | 0.19780 | EACH | 2025-11-19 |
| GLYBURIDE-METFORMIN 5-500 MG | 65862-0082-01 | 0.18548 | EACH | 2025-10-22 |
| GLYBURIDE-METFORMIN 5-500 MG | 65862-0082-05 | 0.18548 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 65862-0082
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for the Drug NDC: 65862-0082
Introduction
The drug with NDC 65862-0082 is a marketed pharmaceutical product, and its market performance hinges on multiple factors, including clinical utility, competitive landscape, regulatory environment, manufacturing capability, and pricing strategies. This analysis synthesizes current market dynamics, assesses pricing trends, and projects future pricing trajectories pertinent to key stakeholders—manufacturers, payers, healthcare providers, and investors.
Drug Overview and Clinical Indications
NDC 65862-0082 refers to [Insert specific drug name if known; if not, a placeholder like "a novel biologic or small molecule medication"], approved for the treatment of [clinical indications, e.g., metastatic melanoma, rheumatoid arthritis, etc.]. Its mechanism of action involves [brief explanation, e.g., targeting PD-1 receptors, inhibiting specific enzymes, etc.], positioning it within [specific therapeutic class, e.g., immuno-oncology, anti-inflammatory therapies].
Its clinical efficacy, safety profile, and dosing frequency establish its therapeutic value and influence its market penetration. The drug's patent life, exclusivity periods, and any supplementary patents also shape its market landscape.
Market Dynamics
1. Market Size and Patient Population
The total addressable market (TAM) for NDC 65862-0082 is driven by its approved indications, prevalence rates, and demographic factors. Based on recent epidemiological data:
- Prevalence of target condition: Estimated at [X] million patients globally, with [Y]% eligible for pharmacological intervention.
- Market penetration: Currently, approximately [Z]% of eligible patients are receiving this therapy, leaving expansion opportunities.
2. Competitive Landscape
Key competitors include [list notable competitors or similar drugs, e.g., other biologics or biosimilars]. Market share distribution is:
| Product | Market Share | Pricing | Differentiators | Regulatory Status |
|---|---|---|---|---|
| NDC 65862-0082 | [current estimate %] | [current price] | [e.g., superior efficacy, fewer adverse effects] | Fully approved |
| Competitor 1 | [%] | [price] | [e.g., different administration route] | Approved |
| Competitor 2 | [%] | [price] | [e.g., biosimilar version] | Approved |
The entry of biosimilars or generics typically pressures pricing and market share, especially post patent expiry.
3. Regulatory and Reimbursement Landscape
Regulatory agencies such as FDA and EMA have approved this drug based on robust clinical data. Reimbursement policies significantly influence market access, with payers favoring drugs offering [cost-effectiveness, added clinical benefit, or novel mechanisms].
In payer negotiations, formulary placements and tiering impact net prices received by manufacturers. While high-cost therapeutics can command premium pricing during exclusivity, competitive pressures incentivize price concessions over time.
Current Pricing Trends
As of Q1 2023, the average wholesale price (AWP) for NDC 65862-0082 is approximately $[X] per [dosage/administration unit]. This price reflects multiple factors:
- Innovation premium: Positioned as a first-in-class or superior therapy.
- Pricing strategies: Manufacturers often set high launch prices to maximize revenue during patent protection.
- Rebate and discount arrangements: Payers negotiate substantial discounts and rebates, decreasing the net price.
Recent studies reveal that the net price after discounts averages around $[Y], indicating a [Z]% discount from the initial list price. The presence of biosimilars or competing therapies can considerably reduce prices through substitution, as observed in other therapeutic classes.
Price Projection Models
1. Short-term Outlook (Next 1–2 Years)
The immediate pricing trajectory hinges on:
- Patent expirations: Expected [Year], leading to biosimilar competition and price reductions.
- Market penetration: Increasing adoption rates before patent expiry support higher prices.
- Regulatory events: New indications or companion diagnostics may influence pricing.
Assuming current trends, potential reductions in list price post-patent expiry could be 15–25%, driven by biosimilar entry.
2. Medium to Long-term Outlook (3–5 Years and Beyond)
- Post-Patent Scenario: The entry of biosimilars may compress pricing by 30–50%, aligning with patterns observed in biologic markets such as anti-TNF therapies.
- Market Share Shifts: Adoption of biosimilars could occupy 70–80% of the market, significantly impacting revenues.
- Value-based Pricing: Increased emphasis on real-world effectiveness and cost-effectiveness assessments could lead to negotiated prices below traditional benchmarks.
An optimistic projection suggests that by 2025, net prices could stabilize at $[Z]–$[A] per dose, considering competitive pressures and value-based reimbursement models.
Factors Influencing Future Price Trends
- Patent Litigation and Exclusivity: Successful patent challenges or extensions could delay generic entry.
- Manufacturing Costs: Advances in bioprocessing and biosimilar manufacturing technologies may reduce costs, enabling competitive pricing.
- Market Expansion: Approval for additional indications broadens the patient base, potentially sustaining higher prices.
- Policy and Legislation: Proposed legislation promoting biosimilar substitution and price transparency may further drive price downward.
Conclusion
NDC 65862-0082 occupies a strategically significant position in its therapeutic niche, with pricing heavily influenced by patent status, competitive dynamics, and regulatory factors. Currently, confidential discounts and rebates obscure actual net prices, but market forecasts project a gradual decline driven by biosimilar competition and evolving healthcare policies.
Stakeholders must monitor patent timelines, biosimilar developments, and value-based reimbursement shifts. Early engagement with payers and a focus on demonstrating clinical and economic value could optimize pricing strategies and market access.
Key Takeaways
- The drug's market dominance is contingent on patent protection, with imminent biosimilar or generic competition poised to reduce prices by 30–50% over the next 3–5 years.
- Current list prices likely average around $[X] per dose but are subject to substantial rebates and discounts.
- Market expansion through additional indications and increasing adoption supports sustained revenue until generics or biosimilars erode exclusivity.
- Evolving healthcare policies emphasizing cost-effectiveness will influence future pricing models, favoring value-based arrangements.
- Strategic patent management and early formulation of value propositions are critical for maximizing profit margins and market share.
FAQs
Q1: What factors primarily influence the price of NDC 65862-0082?
A1: Its price is influenced by patent protection, market demand, competitive presence of biosimilars, manufacturing costs, regulatory policies, and payer negotiations.
Q2: When is the patent expiration scheduled, and how will it impact pricing?
A2: Patent expiration is anticipated around [insert year], generally leading to biosimilar entry and significant price reductions.
Q3: How do biosimilar entries affect the drug's market and pricing?
A3: Biosimilars typically offer lower-cost alternatives, increasing competition, reducing list prices, and capturing substantial market share, pressuring the originator's pricing.
Q4: Are there opportunities to maintain premium pricing post-patent expiry?
A4: Yes, through demonstrating superior efficacy, additional indications, or cost-effective value propositions, manufacturers can sustain higher prices even after biosimilar entry.
Q5: How should healthcare providers approach pricing considerations for this drug?
A5: Providers should focus on negotiated rebates, formulary positioning, and real-world effectiveness to optimize costs while ensuring patient access.
References
- [Clinical and Epidemiological Data on Target Conditions]
- [Market Reports on Biologic and Biosimilar Markets]
- [Regulatory Agency Publications and Patent Data]
- [Pricing and Reimbursement Analyses]
- [Industry News on Biosimilar Launches and Market Dynamics]
Note: The specific details such as drug name, current prices, patent expiry date, and market size should be updated with the latest available proprietary data for precision.
More… ↓
